Manufacturer’s Inserts and efficacy statements:
BayerHepB– 1 dose- 50%, multiple doses (vax schedule)- 70-90%
Testing of participants in 2 national surveys demonstrates no significant decrease in hepatitis B virus infection, despite the availability of hepatitis B vaccine. (AM J Public Health. 1999;89:14-18)
A cost-effective analysis for Medical Decision Making titled Should Canada and the United States Universally Vaccinate Infants against Hepatitis B? suggested that universally vaccinating infants regardless of maternal Hepatitis B carriage status would save the US money in comparison to screening and only vaccinating infants of carrier mothers.
It is concluded that universal vaccination against HBV in infancy is economically attractive, comparable in cost-effectiveness to existing health care interventions. Lower vaccine prices would substantially improve the attractiveness of such a program. Implementation of universal vaccination should be considered in North America, contingent on vaccine price reduction.